Perbedaan Indofarma Tbk. dan Charlie Hospital Semarang Tbk.: Indofarma Tbk. diperdagangkan di Rp126 (kapitalisasi pasar 390,51 M), sedangkan Charlie Hospital Semarang Tbk. diperdagangkan di Rp430 (kapitalisasi pasar 1,11 T, volume 24 jam 25,61 jt). Perbedaan utamanya: Charlie Hospital Semarang Tbk. jauh lebih besar — sekitar 2,8× kapitalisasi pasar Indofarma Tbk.. Mana yang lebih baik tergantung tujuan investasimu.
| INAF | RSCH | |
|---|---|---|
Kapitalisasi Pasar | 390,51 M | 1,11 T |
Volume | — | 25,61 jt |
Lot | — | 256,07 rb |
Perputaran | — | 10,76 M |
Harga Rata-rata | — | 420,16 |
Nilai Transaksi | — | 10,76 M |
Harga Ekuilibrium Indikatif | — | 430 |
Volume Ekuilibrium Indikatif | — | 1,46 rb |
Imbal hasil berjalan pada periode standar
Berita terbaru kedua aset
PT Indonesia Farma Tbk, known as PT Indofarma (Persero) Tbk (the Company) was established based on Deed No. 1 dated January 2, 1996 as amended by Deed No. 134 dated January 26, 1996 both of Notary Sutjipto, SH. PT. Indofarma, Tbk began as medicine factory well known as "Pabrik Obat Manggarai". Then take over by Japan's Government from Nederland's Government on 1942. On 1950 the Indonesian Government acquisited the factory by Department of Health and functioned as center of pharmacy production for its department. On 1979 the name changed to be Department of Health Center of Pharmacy Production as non Profit institution as main assignment to produced medicine for public service. Then the Company changed the name as PT. Indonesia Farma Tbk, known as PT Indofarma (Persero) Tbk.
Selengkapnya di halaman INAF →PT Charlie Hospital Semarang, Tbk (the "Company") was established based on Deed No. 35 dated 11 February 2019, which was made before Notary Nur Hadi, SH, MKn, notary in Kendal Regency and has been approved by the Minister of Law and Human Rights of the Republic of Indonesia based on Decree No. AHU-0008598.AH.01.01. Year 2019 February 11, 2019. The company started its commercial operations on September 23, 2019.
Selengkapnya di halaman RSCH →